BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Art Pappas to moderate panel, "Accessing Capital through Risk-Sharing Models between Early-Stage Companies and Contract Research Organizations" at BIO 2010 in Chicago, IL
News | 05. 05. 2010
